Ginkgo Bioworks Holdings (DNA) Cash from Financing Activities (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly Cash from Financing Activities of -$19000.0 for Q1 2026, up 90.82% year-on-year from -$9957.0 in Q1 2025, and down 100.23% on a QoQ basis from $8.1 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of Cash from Financing Activities data on file, last reported at -$19000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 90.82% year-over-year to -$19000.0; the trailing twelve-month figure through Mar 2026 stood at $18.0 million (up 1731.52% YoY), and the FY2025 full-year result was $17.8 million, up 1122.14% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$19000.0, down from $8.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $97.8 million in Q4 2022 and bottomed at -$1.4 million in Q2 2023.
- The 5-year median for Cash from Financing Activities is -$315000.0 (2023), against an average of $6.4 million.
- The widest annual swing landed in 2022, when Cash from Financing Activities tumbled 175.29%; it then surged 4110.84% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $97.8 million in 2022, then sank by 100.65% to -$632000.0 in 2023, then surged by 67.88% to -$203000.0 in 2024, then soared by 4110.84% to $8.1 million in 2025, then plunged by 100.23% to -$19000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$19000.0 (Q1 2026), $8.1 million (Q4 2025), and $9.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | -19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19,000.00 |
| Mar 31, 2026 | -19,000.00 |
| Dec 31, 2025 | 8.14 Mn |
| Dec 31, 2025 | 8.14 Mn |
| Sep 30, 2025 | 9.94 Mn |
| Sep 30, 2025 | 9.94 Mn |
| Jun 30, 2025 | -98,000.00 |
| Jun 30, 2025 | -98,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Sep 30, 2024 | -465,000.00 |
| Sep 30, 2024 | -465,000.00 |
| Jun 30, 2024 | -226,000.00 |
| Jun 30, 2024 | -226,000.00 |
| Mar 31, 2024 | -845,000.00 |
| Mar 31, 2024 | -845,000.00 |
| Dec 31, 2023 | -632,000.00 |
| Dec 31, 2023 | -632,000.00 |
| Sep 30, 2023 | -315,000.00 |
| Sep 30, 2023 | -315,000.00 |
| Jun 30, 2023 | -1.38 Mn |
| Jun 30, 2023 | -1.38 Mn |
| Mar 31, 2023 | -888,000.00 |
| Mar 31, 2023 | -888,000.00 |
| Dec 31, 2022 | 97.76 Mn |
| Dec 31, 2022 | 97.76 Mn |
| Sep 30, 2022 | -391,000.00 |
| Sep 30, 2022 | -391,000.00 |
| Jun 30, 2022 | -843,000.00 |
| Jun 30, 2022 | -843,000.00 |
| Mar 31, 2022 | -1.19 Mn |
| Mar 31, 2022 | -1.19 Mn |
| Dec 31, 2021 | -11.04 Mn |
| Dec 31, 2021 | -11.04 Mn |
| Sep 30, 2021 | 1.55 Bn |
| Sep 30, 2021 | 1.55 Bn |
| Jun 30, 2021 | -2.12 Mn |
| Jun 30, 2021 | -2.12 Mn |
| Mar 31, 2021 | -433,000.00 |
| Mar 31, 2021 | -433,000.00 |
| Dec 31, 2020 | -186,000.00 |
| Dec 31, 2020 | -186,000.00 |